Cardiology Medical News about statin therapy;inflammatory biomarkers;ACS

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Pre-participation screening of young competitive athletes for prevention of sudden cardiac death

3. The Job Market for 2008-2009: Compensation

4. Renal Artery Stenosis

5. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Relationship of oxidized phospholipids and biomarkers of oxidized low-density lipoprotein with cardiovascular risk factors, inflammatory biomarkers, and effect of statin therapy in patients with acute coronary syndromes: Results From the MIRACL (Myocardial Ischemia Reduction With Aggressive Cholesterol Lowering) trial
JACC - Journal of the American College of Cardiology, 06/08/09

Fraley AE et al. – In pts with acute coronary syndromes (ACS), baseline levels of oxidative biomarkers varied by specific cardiovascular disease (CVD) risk factors and were largely independent of inflammatory biomarkers. Atorvastatin uniformly increased oxidized phospholipids (OxPL)/apolipoprotein B particles (apoB) levels in all subgroups. Future studies must assess whether the increase in OxPL/apoB levels reflects the benefit of effective therapeutic interventions and prediction of new CVD events.

Methods

Study of relationship between oxidative biomarkers, CVD risk factors, and inflammatory and thrombosis biomarkers
Measurement of OxPL/apoB, lipoprotein (a) [Lp(a)], and oxidized low-density lipoprotein (OxLDL) biomarkers
OxLDL biomarkers: immunoglobulin (Ig)G and IgM autoantibodies to malondialdehyde (MDA)-low-density lipoprotein (LDL) and IgG and IgM apoB-100 immune complexes (IC/apoB)
Assessment at baseline and after 16 wks of treatment with atorvastatin 80 mg/day or placebo
Subjects: 2,342 ACS pts enrolled in MIRACL

Results

At baseline, potentially atheroprotective IgM autoantibodies and IgM IC/apoB lower in male pts, diabetic pts, and pts age >65 yrs
Higher levels of OxPL/apoB, Lp(a), and OxLDL biomarkers for pts with LDL levels greater vs less than the median (122 mg/dL)
Atorvastatin resulted in significantly larger changes in all biomarkers in female pts, pts age <65 yrs, pts with LDL cholesterol <122 mg/dl, nonsmokers, and nondiabetic pts
A significant increase in OxPL/apoB in response to atorvastatin in all 20 subgroups
Weak or no significant correlations between all OxLDL biomarkers and C-reactive protein, serum amyloid A, tissue plasminogen activator, interleukin-6, intercellular adhesion molecule, vascular cell adhesion molecule, P-selectin, and E-selectin at randomization and 16 wks

<< Previous
Antihypertensive treatment after stroke and all-cause mortality –...

Next >>
Beta-blockade with nebivolol in elderly heart failure patients...